Foresite Capital Management VI LLC Buys New Stake in Centessa Pharmaceuticals plc (NASDAQ:CNTA)

Foresite Capital Management VI LLC purchased a new position in shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 1,253,379 shares of the company's stock, valued at approximately $20,994,000. Centessa Pharmaceuticals makes up approximately 9.4% of Foresite Capital Management VI LLC's holdings, making the stock its 3rd biggest holding. Foresite Capital Management VI LLC owned approximately 0.95% of Centessa Pharmaceuticals at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Geode Capital Management LLC boosted its position in Centessa Pharmaceuticals by 1.2% during the 4th quarter. Geode Capital Management LLC now owns 57,257 shares of the company's stock valued at $959,000 after acquiring an additional 660 shares in the last quarter. GAMMA Investing LLC lifted its stake in shares of Centessa Pharmaceuticals by 29.1% during the 4th quarter. GAMMA Investing LLC now owns 3,837 shares of the company's stock worth $64,000 after purchasing an additional 865 shares during the last quarter. Barclays PLC boosted its position in Centessa Pharmaceuticals by 1,414.9% during the fourth quarter. Barclays PLC now owns 5,302 shares of the company's stock valued at $89,000 after purchasing an additional 4,952 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its stake in Centessa Pharmaceuticals by 39.1% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 18,909 shares of the company's stock valued at $317,000 after purchasing an additional 5,316 shares during the last quarter. Finally, Franklin Resources Inc. raised its holdings in Centessa Pharmaceuticals by 0.3% in the fourth quarter. Franklin Resources Inc. now owns 2,308,546 shares of the company's stock worth $38,668,000 after purchasing an additional 6,000 shares in the last quarter. Hedge funds and other institutional investors own 82.01% of the company's stock.

Analyst Ratings Changes

A number of brokerages have recently issued reports on CNTA. Guggenheim reaffirmed a "buy" rating and issued a $28.00 price objective on shares of Centessa Pharmaceuticals in a research report on Wednesday, March 26th. Morgan Stanley reaffirmed an "overweight" rating and issued a $27.00 price target on shares of Centessa Pharmaceuticals in a report on Friday, March 7th. TD Cowen initiated coverage on Centessa Pharmaceuticals in a report on Tuesday, January 7th. They set a "buy" rating for the company. Finally, Piper Sandler began coverage on Centessa Pharmaceuticals in a research note on Monday, March 31st. They set an "overweight" rating and a $38.00 target price on the stock. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has an average rating of "Buy" and an average target price of $27.71.

Insider Buying and Selling

In other news, insider Karen M. Anderson sold 6,471 shares of the company's stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $16.86, for a total value of $109,101.06. Following the sale, the insider now directly owns 54,322 shares of the company's stock, valued at $915,868.92. This represents a 10.64 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Saurabh Saha sold 55,000 shares of the firm's stock in a transaction on Thursday, February 20th. The stock was sold at an average price of $15.93, for a total transaction of $876,150.00. Following the transaction, the chief executive officer now directly owns 331,017 shares of the company's stock, valued at approximately $5,273,100.81. This trade represents a 14.25 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 219,824 shares of company stock worth $3,581,039. 11.59% of the stock is owned by company insiders.

Centessa Pharmaceuticals Stock Performance

Shares of CNTA traded up $0.11 during trading hours on Friday, reaching $13.61. 749,858 shares of the company traded hands, compared to its average volume of 614,268. The stock has a market capitalization of $1.81 billion, a P/E ratio of -8.90 and a beta of 1.53. The company has a quick ratio of 21.52, a current ratio of 21.52 and a debt-to-equity ratio of 0.15. The business has a fifty day moving average price of $14.17 and a 200-day moving average price of $15.79. Centessa Pharmaceuticals plc has a 12-month low of $7.75 and a 12-month high of $19.09.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last announced its quarterly earnings data on Monday, March 24th. The company reported ($0.34) earnings per share for the quarter, beating analysts' consensus estimates of ($0.38) by $0.04. Equities analysts anticipate that Centessa Pharmaceuticals plc will post -1.6 EPS for the current fiscal year.

Centessa Pharmaceuticals Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.